Modeling and Simulation - PK/PD Archives | Page 11 of 37 | Certara

On-Demand Webinar

How to Perform Level C IVIVC in Phoenix

Step-by-step guidance for Level C IVIVC studies.

CertaraDecember 13, 2017

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

CertaraNovember 1, 2017

Publication

A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies

CertaraOctober 30, 2017

Publication

Influence of Molecular Size on the Clearance of Antibody Fragments

CertaraOctober 1, 2017

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

CertaraAugust 1, 2017

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

CertaraJuly 15, 2017

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

CertaraJuly 1, 2017

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

CertaraJune 1, 2017

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

CertaraJune 1, 2017

© 2025 Certara. All Rights Reserved. | Privacy policy